SODIUM CHLORIDE BRAUN 5,85% infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

sodium chloride braun 5,85% infusioonilahuse kontsentraat

b. braun melsungen ag - naatriumkloriid - infusioonilahuse kontsentraat - 5,85% 20ml 20tk

OLIMEL N7E infusiooniemulsioon Eesti - eesti - Ravimiamet

olimel n7e infusiooniemulsioon

baxter - kombinatsioonid - infusiooniemulsioon - 2000ml 4tk; 1500ml 4tk

OLIMEL PERI N4E infusiooniemulsioon Eesti - eesti - Ravimiamet

olimel peri n4e infusiooniemulsioon

baxter - kombinatsioonid - infusiooniemulsioon - 1000ml 6tk; 2000ml 4tk; 2500ml 2tk; 1500ml 4tk

ORALAIR 100 IR & 300 IR keelealune tablett Eesti - eesti - Ravimiamet

oralair 100 ir & 300 ir keelealune tablett

stallergenes - heintaimede õietolm - keelealune tablett - 100ir/300ir 3tk / 28tk

PRAMIPEXOLE ORION tablett Eesti - eesti - Ravimiamet

pramipexole orion tablett

orion corporation - pramipeksool - tablett - 0,18mg 100tk; 0,18mg 30tk

GLUCOSE B. BRAUN 5% infusioonilahus Eesti - eesti - Ravimiamet

glucose b. braun 5% infusioonilahus

b. braun melsungen ag - süsivesikud - infusioonilahus - 5% 500ml 10tk

OLIMEL N9E infusiooniemulsioon Eesti - eesti - Ravimiamet

olimel n9e infusiooniemulsioon

baxter - kombinatsioonid - infusiooniemulsioon - 1500ml 4tk; 2000ml 4tk; 1000ml 6tk

XENAZINE tablett Eesti - eesti - Ravimiamet

xenazine tablett

pharmaswiss ceska republika s.r.o. - tetrabenasiin - tablett - 25mg 112tk

Phelinun Euroopa Liit - eesti - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Thiotepa Riemser Euroopa Liit - eesti - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastilised ained - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.